Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.
Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. Epub 2011 Dec 27.
Related citations
Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.
Belser JA, Sleeman K, Pearce MB, Katz JM, Gubareva LV, Tumpey TM.
Antimicrob Agents Chemother. 2012 Mar;56(3):1616-8. Epub 2011 Dec 12.
Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.
Gilca R, Fortin E, Frenette C, Longtin Y, Gourdeau M.
Antimicrob Agents Chemother. 2012 Feb;56(2):639-46. Epub 2011 Nov 21.
Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T.
Antimicrob Agents Chemother. 2012 Jan;56(1):369-77. Epub 2011 Oct 24.
Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.
Kumar N, Sharma NR, Ly H, Parslow TG, Liang Y.
Antimicrob Agents Chemother. 2011 Dec;55(12):5553-9. Epub 2011 Sep 19.
Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.
Hsu JT, Yeh JY, Lin TJ, Li ML, Wu MS, Hsieh CF, Chou YC, Tang WF, Lau KS, Hung HC, Fang MY, Ko S, Hsieh HP, Horng JT.
Antimicrob Agents Chemother. 2012 Feb;56(2):647-57. Epub 2011 Sep 19.
Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.
Kitano M, Itoh Y, Kodama M, Ishigaki H, Nakayama M, Ishida H, Baba K, Noda T, Sato K, Nihashi Y, Kanazu T, Yoshida R, Torii R, Sato A, Ogasawara K.
Antimicrob Agents Chemother. 2011 Nov;55(11):4961-70. Epub 2011 Aug 15.
Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J; S-021812 Clinical Study Group.
Antimicrob Agents Chemother. 2011 Nov;55(11):5267-76. Epub 2011 Aug 8.
Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.
Duan S, Boltz DA, Li J, Oshansky CM, Marjuki H, Barman S, Webby RJ, Webster RG, Govorkova EA.
Antimicrob Agents Chemother. 2011 Oct;55(10):4718-27. Epub 2011 Jul 5.
Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus.
Naughtin M, Dyason JC, Mardy S, Sorn S, von Itzstein M, Buchy P.
Antimicrob Agents Chemother. 2011 May;55(5):2004-10. Epub 2011 Feb 22.
Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.
Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J; S-021812 Clinical Study Group.
Antimicrob Agents Chemother. 2011 Jun;55(6):2803-12. Epub 2011 Apr 4.
Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B.
Antimicrob Agents Chemother. 2011 Jun;55(6):2942-52. Epub 2011 Mar 21.
Immunotherapy with a combination of intravenous immune globulin and p4 peptide rescues mice from postinfluenza pneumococcal pneumonia.
Weeks JN, Boyd KL, Rajam G, Ades EW, McCullers JA.
Antimicrob Agents Chemother. 2011 May;55(5):2276-81. Epub 2011 Mar 7.
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.
Antimicrob Agents Chemother. 2011 Apr;55(4):1740-6. Epub 2011 Jan 24.
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.
Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53. Epub 2011 Jan 24.
Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses.
Zheng Q, Xia L, Wu WL, Zheng Z, Huo Y, Wu J, Liu Y, Yu H, Chen Y, Lau SY, Chen H, Luo W, Xia N.
Antimicrob Agents Chemother. 2011 Apr;55(4):1349-57. Epub 2011 Jan 18.
Identification of the minimal active sequence of an anti-influenza virus peptide.
Jones JC, Settles EW, Brandt CR, Schultz-Cherry S.
Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3. Epub 2011 Jan 10.
High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.
Giraud C, Manceau S, Oualha M, Chappuy H, Mogenet A, Duchêne P, Ducrocq S, Hubert P, Treluyer JM.
Antimicrob Agents Chemother. 2011 Jan;55(1):433-5. Epub 2010 Oct 11.
Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase.
Wunderlich K, Juozapaitis M, Ranadheera C, Kessler U, Martin A, Eisel J, Beutling U, Frank R, Schwemmle M.
Antimicrob Agents Chemother. 2011 Feb;55(2):696-702. Epub 2010 Dec 6.
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
Rouan MC, Gevers T, Roymans D, de Zwart L, Nauwelaers D, De Meulder M, van Remoortere P, Vanstockem M, Koul A, Simmen K, Andries K.
Antimicrob Agents Chemother. 2010 Nov;54(11):4534-9. Epub 2010 Sep 7.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on